Complex Percutaneous Coronary Intervention in Patients Requiring Transcatheter Aortic Valve Replacement Authors: Thomas Gilliland, Tanush Gupta Published: 2026 The 2020 American Heart Association/American College of Cardiology1 and 2025 European Society of Cardiology guidelines2 recommend coronary revascularization with percutaneous coronary intervention (PCI) before transcatheter aortic valve implantation (TAVI) for significant proximal coronary artery disease (CAD) (class of recommendation IIa and IIb, respectively). In the European Society of Cardiology guidelines, where the coronary stenosis is >90%, the class of recommendation is increased to IIa. This recommendation stems from findings of the NOTION-3 trial in which treatment of angiographic stenoses ≥90% or fractional flow reserve ≤0.80 with PCI before TAVI reduced the 2-year risk of death, myocardial infarction, or urgent revascularization compared to TAVI alone (Table 1).3 Patients with complex left main or left main equivalent disease were excluded from this trial, as were patients with multiple chronic total occlusions (CTOs).Table 1Completed or ongoing trials evaluating percutaneous coronary revascularization in patients undergoing transcatheter aortic valve implantationTrial (NCT)Number and enrollment periodStudy designKey inclusion criteriaKey exclusion criteriaKey findingsNOTION-3 (NCT03058627)No. = 455, 2017–2022RCT comparing PCI to medical therapy. PCI performed before or up to 2 days after TAVI. Primary outcome a composite of all-cause mortality, MI, or urgent revascularization at 1 year.Symptomatic severe AS and obstructive CAD in an epicardial vessel ≥2.5 mm (FFR ≤0.80 or ≥90% angiographic stenosis).Limited life expectancy, severe renal failure, recent acute coronary syndrome, left main coronary stenosis.Decrease in primary outcome in the PCI group (26 versus 36%, p = 0.04) driven by reduced MI and urgent revascularization.ACTIVATION (ISRCTN75836930)No. = 235, 2012–2019RCT comparing PCI to medical therapy. Noninferiority design. PCI performed before TAVI. Primary endpoint a composite of all-cause death or rehospitalization at 1 year.Symptomatic severe AS and ≥1 coronary stenosis ≥70%.Recent acute coronary syndrome, unprotected left main coronary stenosis, Canadian Cardiovascular Society class ≥3 angina.No difference in the primary composite endpoint (41.5% PCI versus 44.0% no PCI). Trial terminated early for slow enrollment.FAITAVI (NCT03360591)No. = 320, 2017–2024RCT comparing angiography versus FFR-guided PCI occurring before, at the time of, or within 1 month after TAVI. Primary endpoint a composite of all-cause death, MI, stroke, major bleeding, need for target vessel revascularization at 12 months.Symptomatic severe AS and ≥1 coronary stenosis ≥50%.Impaired left ventricular function, acute coronary syndrome, life expectancy <1 year.Decrease in primary outcome in the FFR-guided PCI group (8.5 versus 16% in the angiography-guided PCI group, p = 0.047), with greatest reductions in overall mortality and ischemia-driven target vessel revascularization.COMPLETE-TAVR (NCT04634240)Estimated No. = 4000, 2020–presentRCT comparing PCI to medical therapy. PCI of all suitable lesions performed 1–45 days after TAVI with a balloon-expandable transcatheter heart valve. Primary outcome a composite of cardiovascular death, new MI, ischemia-driven revascularization, or hospitalization for unstable angina or heart failure over median 3.5-year follow-up.Symptomatic severe AS and ≥1 coronary stenosis ≥70% in an epicardial vessel ≥2.5 mm.Prior PCI within 90 days of TAVI, recent acute coronary syndrome, life expectancy <5 years, prior CABG, LVEF <30%, severe renal insufficiency.Study ongoing (currently enrolling).TAVI-PCI (NCT04310046)Estimated No. = 986, 2020–2025RCT comparing PCI before TAVI (1–45 days) versus after TAVI (1–45 days) with a balloon-expandable transcatheter heart valve. Primary outcome a composite of all-cause death, nonfatal MI, ischemia-driven revascularization, valve- or procedure-related rehospitalization, or life-threatening/disabling or major bleeding at 1 year.Symptomatic severe AS and ≥1 coronary stenosis in an epicardial vessel ≥2.5 mm.Recent acute coronary syndrome, PCI within 3 months before randomization, previous CABG, Syntax Score ≥33, life expectancy <1 year.Study ongoing (active, not recruiting).PRO-TAVI (NCT05078619)No. = 466, 2021–2024RCT comparing PCI to medical therapy. PCI performed within 2 weeks before TAVI. Primary outcome a composite of all-cause mortality, MI, stroke, and VARC-3 type 2–4 bleeding at 12 months.Symptomatic severe AS and ≥1 coronary stenosis of ≥70% or 40%–70% when positive by hemodynamics in an epicardial vessel ≥2.5 mm.Unprotected left main or left main equivalent stenosis, life expectancy <1 year.No difference in the primary composite endpoint (24% in the medical therapy group and 26% in the PCI group, p = 0.0008 for noninferiority).Abbreviations: AS, aortic stenosis; CABG, coronary artery bypass graft; CAD, coronary artery disease; FFR, fractional flow reserve; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NCT, National Clinical Trial identifier; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; TAVI, transcatheter aortic valve implantation. Table 1Completed or ongoing trials evaluating percutaneous coronary revascularization in patients undergoing transcatheter aortic valve implantationTrial (NCT)Number and enrollment periodStudy designKey inclusion criteriaKey exclusion criteriaKey findingsNOTION-3 (NCT03058627)No. = 455, 2017–2022RCT comparing PCI to medical therapy. PCI performed before or up to 2 days after TAVI. Primary outcome a composite of all-cause mortality, MI, or urgent revascularization at 1 year.Symptomatic severe AS and obstructive CAD in an epicardial vessel ≥2.5 mm (FFR ≤0.80 or ≥90% angiographic stenosis).Limited life expectancy, severe renal failure, recent acute coronary syndrome, left main coronary stenosis.Decrease in primary outcome in the PCI group (26 versus 36%, p = 0.04) driven by reduced MI and urgent revascularization.ACTIVATION (ISRCTN75836930)No. = 235, 2012–2019RCT comparing PCI to medical therapy. Noninferiority design. PCI performed before TAVI. Primary endpoint a composite of all-cause death or rehospitalization at 1 year.Symptomatic severe AS and ≥1 coronary stenosis ≥70%.Recent acute coronary syndrome, unprotected left main coronary stenosis, Canadian Cardiovascular Society class ≥3 angina.No difference in the primary composite endpoint (41.5% PCI versus 44.0% no PCI). Trial terminated early for slow enrollment.FAITAVI (NCT03360591)No. = 320, 2017–2024RCT comparing angiography versus FFR-guided PCI occurring before, at the time of, or within 1 month after TAVI. Primary endpoint a composite of all-cause death, MI, stroke, major bleeding, need for target vessel revascularization at 12 months.Symptomatic severe AS and ≥1 coronary stenosis ≥50%.Impaired left ventricular function, acute coronary syndrome, life expectancy <1 year.Decrease in primary outcome in the FFR-guided PCI group (8.5 versus 16% in the angiography-guided PCI group, p = 0.047), with greatest reductions in overall mortality and ischemia-driven target vessel revascularization.COMPLETE-TAVR (NCT04634240)Estimated No. = 4000, 2020–presentRCT comparing PCI to medical therapy. PCI of all suitable lesions performed 1–45 days after TAVI with a balloon-expandable transcatheter heart valve. Primary outcome a composite of cardiovascular death, new MI, ischemia-driven revascularization, or hospitalization for unstable angina or heart failure over median 3.5-year follow-up.Symptomatic severe AS and ≥1 coronary stenosis ≥70% in an epicardial vessel ≥2.5 mm.Prior PCI within 90 days of TAVI, recent acute coronary syndrome, life expectancy <5 years, prior CABG, LVEF <30%, severe renal insufficiency.Study ongoing (currently enrolling).TAVI-PCI (NCT04310046)Estimated No. = 986, 2020–2025RCT comparing PCI before TAVI (1–45 days) versus after TAVI (1–45 days) with a balloon-expandable transcatheter heart valve. Primary outcome a composite of all-cause death, nonfatal MI, ischemia-driven revascularization, valve- or procedure-related rehospitalization, or life-threatening/disabling or major bleeding at 1 year.Symptomatic severe AS and ≥1 coronary stenosis in an epicardial vessel ≥2.5 mm.Recent acute coronary syndrome, PCI within 3 months before randomization, previous CABG, Syntax Score ≥33, life expectancy <1 year.Study ongoing (active, not recruiting).PRO-TAVI (NCT05078619)No. = 466, 2021–2024RCT comparing PCI to medical therapy. PCI performed within 2 weeks before TAVI. Primary outcome a composite of all-cause mortality, MI, stroke, and VARC-3 type 2–4 bleeding at 12 months.Symptomatic severe AS and ≥1 coronary stenosis of ≥70% or 40%–70% when positive by hemodynamics in an epicardial vessel ≥2.5 mm.Unprotected left main or left main equivalent stenosis, life expectancy <1 year.No difference in the primary composite endpoint (24% in the medical therapy group and 26% in the PCI group, p = 0.0008 for noninferiority).Abbreviations: AS, aortic stenosis; CABG, coronary artery bypass graft; CAD, coronary artery disease; FFR, fractional flow reserve; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NCT, National Clinical Trial identifier; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; TAVI, transcatheter aortic valve implantation. Completed or ongoing trials evaluating percutaneous coronary revascularization in patients undergoing transcatheter aortic valve implantation Abbreviations: AS, aortic stenosis; CABG, coronary artery bypass graft; CAD, coronary artery disease; FFR, fractional flow reserve; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NCT, National Clinical Trial identifier; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; TAVI, transcatheter aortic valve implantation. The Aortic Stenosis with Complex PCI (ASCoP) registry (NCT05750927) collects data on patients undergoing TAVI and complex high-risk indicated PCI (CHIP).4 CHIP is defined as the presence of 1 or more of the following: left main or left main equivalent disease, three-vessel PCI, PCI of a last remaining vessel, bifurcation PCI, severe calcification requiring debulking, lesion length ≥30 mm, revascularization where the left ventricular ejection fraction is ≤30%, and any PCI requiring concomitant mechanical circulatory support. The current study includes patients enrolled 2013 to 2023 who underwent staged PCI and TAVI. Staged PCI was defined as occurring before, during, or up to 6 months after TAVI. The majority of patients underwent PCI before TAVI, whereas fewer than 10% underwent PCI after TAVI. Patients with complete revascularization (CR) versus incomplete revascularization (IR) were compared. CR was defined as revascularization of any ≥70% stenosis in an epicardial vessel ≥2.5 mm in diameter or >50% in the left main coronary artery. The primary outcome was a composite of all-cause death and unplanned hospitalization for cardiovascular causes. There were no differences in the primary outcome between IR and CR patients at 30 days and 1 year. CR patients were less likely to experience an unplanned cardiovascular hospitalization at 1 year (14.81% in the CR group versus 22.80% in the IR group; p = 0.036). This difference remained significant in a propensity score-adjusted analysis. Baseline differences between the CR and IR groups included a higher incidence of chronic kidney disease and prior coronary artery bypass graft in the IR group and a higher incidence of diabetes in the CR group. IR patients were more likely to undergo left main PCI and bifurcation PCI, have three-vessel disease, require mechanical circulatory support during PCI, and have more than 1 CHIP criterion. IR patients were significantly more likely to receive a self-expanding TAVI (74.5% in the IR group compared to 63.2% in the CR group). In-hospital stroke, bleeding, and acute kidney injury were uncommon and did not differ between groups. This study demonstrates the feasibility of complex PCI in patients undergoing TAVI, which was primarily performed before valve replacement, and it suggests that CR in patients with complex CAD may provide downstream benefit. Intended PCI was successful in >98% of patients, and complications rates were low. Mechanical circulatory support was used in 18 patients with less than 2% mortality at 30 days, and >25% of CR patients and >50% of IR patients underwent left main PCI. Several caveats should be stressed. This is a retrospective analysis of patients undergoing complex PCI over the course of a decade. First, confounding variables may not be entirely accounted for, and the baseline characteristics clearly indicate that the patients achieving CR versus IR are different. IR patients had more complex CAD and may have been an overall sicker cohort. Second, IR patients were more likely to receive self-expanding valves. This may reflect different practice patterns among enrolling sites and could serve as a marker of the severity of comorbid illness and operators’ expectation of need for future coronary reaccess. Third, there is no comparator group of medical therapy. Ultimately, the long-term benefit of revascularization of both complex and noncomplex CAD beyond optimal medical therapy remains an undetermined area of active investigation. Completed and ongoing clinical trials aimed at comparing PCI with medical therapy and determination of the optimal timing of PCI and modality of CAD assessment in patients undergoing TAVI are summarized in Table 1.5, 6, 7, 8, 9 Although the results of the ASCoP registry are encouraging, these findings should not be considered as directly extending the NOTION-3 randomized trial findings. NOTION-3 excluded many patients with the types of lesions explored in ASCoP (i.e., left main disease and CTOs), had a comparator group of medical therapy alone rather than IR, and only included patients undergoing PCI before TAVI. Although the results of the ASCoP registry should not be considered practice changing, they do bolster the feasibility and safety of CR for selected patients prior, during, or after TAVI. ASCoP cannot guide clinicians on the need for a CTO intervention in elderly, frail patients with a low burden of angina after TAVR. On the other hand, for younger patients with refractory angina post TAVI, ASCoP provides reassurance that left main, CTO, and other high-risk PCI attempts at CR are feasible and potentially beneficial. Disclosure Statement Dr Gilliland reports no relevant financial disclosures. Dr Gupta reports consulting for Medtronic.